UNSPSC 51183614: Insulin human

This classification denotes a therapeutic insulin with the molecular formula C257H383N65O77S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 1Y17CTI5SR, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183614 Insulin human is a Commodity code. State and local governments buy pharmaceutical products — insulin formulations in particular, but also a broader spectrum of generic multi-source drugs and over-the-counter medications — through cooperative purchasing vehicles that establish master contracts with manufacturers, who then supply through authorized wholesalers at negotiated pricing. The work involves product sourcing, regulatory compliance (FDA registration, cGMP certification, Drug Supply Chain Security Act compliance), supply-chain logistics through specific wholesaler networks, and pricing administration across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted the most recent opportunity on this code: a Request for Proposal issued January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities including Oregon. MMCAP requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of them with chargeback systems in place, and submit detailed product information including National Drug Codes, SKUs, UPCs, and manufacturing locations. Evaluation is weighted heavily toward price competitiveness (75 percent), with the remainder split across fixed pricing compliance (10 percent), administrative fee format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Products must be available in the marketplace by May 15, 2026, with contracts effective July 1, 2026. The contract term runs two years for new responders with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028. No specific award value or budget range was disclosed; vendors should anticipate performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials.